Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Acino Holding AG's share price for the quarter that ended in Dec. 2013 was CHF113.6. Acino Holding AG's Shares Outstanding (EOP) for the quarter that ended in Dec. 2013 was 3.4 Mil. Therefore, Acino Holding AG's market cap for the quarter that ended in Dec. 2013 was CHF387.7 Mil.
Acino Holding AG's quarterly market cap
increased
from Dec. 2011 (CHF348.1 Mil) to Dec. 2012 (CHF375.1 Mil) and
increased
from Dec. 2012 (CHF375.1 Mil) to Dec. 2013 (CHF387.7 Mil).
Acino Holding AG's annual market cap
increased
from Dec. 2011 (CHF348.1 Mil) to Dec. 2012 (CHF375.1 Mil) and
increased
from Dec. 2012 (CHF375.1 Mil) to Dec. 2013 (CHF387.7 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Acino Holding AG's Enterprise Value for Today is CHF393.1 Mil.
Acino Holding AG Market Cap Historical Data
The historical data trend for Acino Holding AG's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Acino Holding AG's Market Cap
For the Drug Manufacturers - General subindustry, Acino Holding AG's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acino Holding AG's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Acino Holding AG's Market Cap distribution charts can be found below:
* The bar in red indicates where Acino Holding AG's Market Cap falls into.
Acino Holding AG Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Acino Holding AG's Market Cap for the fiscal year that ended in Dec. 2013 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acino Holding AG (XSWX:ACIN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Acino Holding AG Market Cap Related Terms
Thank you for viewing the detailed overview of Acino Holding AG's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Acino Holding AG is a Switzerland-based company engaged in the pharmaceutical industry. The Company develops, manufactures, and markets pharmaceuticals in novel drug delivery forms internationally. It is divided into four segments Business to Consumer (BtC); Business to Business (BtB); Technology marketing (TM); and Production (Prod). The BtC segment comprises all direct marketing activities. Under the company's "Acino Switzerland" brand and, with the promise of Swiss quality, the company sells its products in emerging markets around the globe. This reporting segment includes the business purchased from Mepha/Cephalon in the Middle East, Africa, Latin America and Asia. The BtB segment comprises Acino's business with its internally developed products, for which the company also owns the intellectual property rights. Acino develops and produces high-quality medicines with proven active ingredients and modern drug delivery systems and grants licenses for them to leading pharmaceutical and generic pharmaceutical companies worldwide. The technology marketing segment comprises a broad spectrum of fully integrated contract services, including procurement, contract development, production and packaging for companies in the life sciences industry. On behalf of these customers, Acino develops a comprehensive product pipeline on the basis of its special technological know-how. This includes both new types of medicines as well as projects with innovative drug delivery systems for established active ingredients. The production segment is responsible for the manufacturing of products and the supplying of the other three segments, and generates turnover through the reimbursement of its services. The manufacturing costs of products are credited to the production segment at standard prices along with remuneration in the form of a mark-up for materials and production costs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSWX:ACIN has been successfully added to your 